Civic Intelligence

Oligo Nation Inc

990EZ • Fiscal year 2014 • EIN 46-3087590

Jan 01, 2014 to Dec 31, 2014

Sebastopol, CA
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

67th percentile

0.03x

Higher debt load relative to assets than 67% of similar nonprofits.

2014 filings • 501(c)3 • <$500k nonprofits • Source year 2014

Liabilities / Revenue

70th percentile

0.03x

Higher debt load relative to revenue than 70% of similar nonprofits.

2014 filings • 501(c)3 • <$500k nonprofits • Source year 2014

Net Margin

99th percentile

97%

Higher net margin than 99% of similar nonprofits.

2014 filings • 501(c)3 • <$500k nonprofits • Source year 2014

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2014

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2014

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2014

Assets

$100,612

No earlier filing loaded for comparison.

Net Assets

-

No earlier filing loaded for comparison.

Liabilities

$2,570

No earlier filing loaded for comparison.

Revenue

$100,612

No earlier filing loaded for comparison.

Expenses

$2,570

No earlier filing loaded for comparison.

Net Income

$98,042

No earlier filing loaded for comparison.

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$3.0M$2.0M$1.0M$0Assets 2014: $100,612Liabilities 2014: $2,5702014Assets 2015: $246,377Liabilities 2015: $3,7742015Assets 2016: $470,833Liabilities 2016: $95,956Net Assets 2016: $374,8772016Assets 2017: $610,615Liabilities 2017: $96,960Net Assets 2017: $513,6552017Assets 2018: $650,125Liabilities 2018: $192,674Net Assets 2018: $457,4512018Assets 2019: $768,430Liabilities 2019: $177,025Net Assets 2019: $591,4052019Assets 2020: $1,418,298Liabilities 2020: $127,636Net Assets 2020: $1,290,6622020Assets 2021: $1,684,218Liabilities 2021: $277,289Net Assets 2021: $1,406,9292021Assets 2022: $2,266,505Liabilities 2022: $200,302Net Assets 2022: $2,066,2032022Assets 2023: $2,061,936Liabilities 2023: $131,000Net Assets 2023: $1,930,9362023Assets 2024: $2,572,438Liabilities 2024: $126,499Net Assets 2024: $2,445,9392024

Highlighted filing

2014

Assets$100,612
Liabilities$2,570
Net Assets-

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$2.0M$1.0M$0-$1.0MRevenue 2014: $100,612Expenses 2014: $2,570Net Income 2014: $98,0422014Revenue 2015: $149,840Expenses 2015: $5,279Net Income 2015: $144,5612015Revenue 2016: $383,557Expenses 2016: $112,321Net Income 2016: $271,2362016Revenue 2017: $214,247Expenses 2017: $67,276Net Income 2017: $146,9712017Revenue 2018: $335,573Expenses 2018: $291,603Net Income 2018: $43,9702018Revenue 2019: $492,468Expenses 2019: $379,380Net Income 2019: $113,0882019Revenue 2020: $927,609Expenses 2020: $273,611Net Income 2020: $653,9982020Revenue 2021: $672,520Expenses 2021: $556,253Net Income 2021: $116,2672021Revenue 2022: $978,352Expenses 2022: $319,078Net Income 2022: $659,2742022Revenue 2023: $1,637,244Expenses 2023: $1,778,009Net Income 2023: -$140,7652023Revenue 2024: $1,893,730Expenses 2024: $1,441,227Net Income 2024: $452,5032024

Highlighted filing

2014

Revenue$100,612
Expenses$2,570
Net Income$98,042
Filing Detail Status

This 2014 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

Jump To
Filing Snapshot
Filing Period
Jan 1, 2014 to Dec 31, 2014
Mission and Program Overview

Mission

Oligo nation advocates and fundraises to support medical research into oligodendroglioma brain cancer. We engage with others in the oligodendroglioma community to raise money and we work with researchers and research institutions to identify opportunities to fund translational research that can potentially lead to new treatments in the next 5 years.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings